U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's ...

Sen. Elizabeth Warren urges FTC to scrutinize Novo Nordisk's $16.5 billion acquisition of Catalent over concerns of increased ...

The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added to ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give ...

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

On Thursday, Catalent Inc (CTLT) stock saw a decline, ending the day at $60.71 which represents a decrease of $-0.25 or -0.41% from the prior close of $60.96. The stock opened at $60.78 and touched a ...

Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup ...

U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission “closely scrutinize” a $16.5 billion deal in which Novo ...

On Monday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $60.61 which represents a slight increase of $0.02 or 0.03% from the prior close of $60.59. The stock opened at $60.53 and ...

The phase 3 clinical trial is a randomized, double-blind, three-arm study comparing MELT-300, sublingual midazolam, and ...